The stock price of Pulse Biosciences Inc (NASDAQ: PLSE) has jumped by 8.31 compared to previous close of 7.22. Despite this, the company has seen a gain of 3.99% in its stock price over the last five trading days. Business Wire reported 2024-03-14 that HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do s.
Is It Worth Investing in Pulse Biosciences Inc (NASDAQ: PLSE) Right Now?
PLSE has 36-month beta value of 1.73. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PLSE is 16.23M, and currently, short sellers hold a 16.18% ratio of that float. The average trading volume of PLSE on April 16, 2024 was 174.78K shares.
PLSE’s Market Performance
PLSE’s stock has seen a 3.99% increase for the week, with a -23.63% drop in the past month and a -2.62% fall in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 7.36% for Pulse Biosciences Inc The simple moving average for the past 20 days is -6.29% for PLSE’s stock, with a 5.35% simple moving average for the past 200 days.
Analysts’ Opinion of PLSE
Many brokerage firms have already submitted their reports for PLSE stocks, with Stephens repeating the rating for PLSE by listing it as a “Overweight.” The predicted price for PLSE in the upcoming period, according to Stephens is $28 based on the research report published on July 27, 2021 of the previous year 2021.
Maxim Group, on the other hand, stated in their research note that they expect to see PLSE reach a price target of $40. The rating they have provided for PLSE stocks is “Buy” according to the report published on March 11th, 2021.
H.C. Wainwright gave a rating of “Buy” to PLSE, setting the target price at $40 in the report published on January 26th of the previous year.
PLSE Trading at -12.96% from the 50-Day Moving Average
After a stumble in the market that brought PLSE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.58% of loss for the given period.
Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares sank -24.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.92% lower at present.
During the last 5 trading sessions, PLSE rose by +3.99%, which changed the moving average for the period of 200-days by +18.66% in comparison to the 20-day moving average, which settled at $8.22. In addition, Pulse Biosciences Inc saw -36.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLSE starting from DUGGAN ROBERT W, who purchase 17,999 shares at the price of $9.15 back on Dec 12 ’23. After this action, DUGGAN ROBERT W now owns 36,984,179 shares of Pulse Biosciences Inc, valued at $164,691 using the latest closing price.
DUGGAN ROBERT W, the Director of Pulse Biosciences Inc, purchase 90,118 shares at $9.36 during a trade that took place back on Dec 11 ’23, which means that DUGGAN ROBERT W is holding 36,966,180 shares at $843,504 based on the most recent closing price.
Stock Fundamentals for PLSE
The total capital return value is set at -0.81. Equity return is now at value -200.47, with -59.70 for asset returns.
Based on Pulse Biosciences Inc (PLSE), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -3.61. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -58.33.
Currently, EBITDA for the company is -42.37 million with net debt to EBITDA at 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.76.
Conclusion
To put it simply, Pulse Biosciences Inc (PLSE) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
